Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Trientine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 7/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA6 | P23280 | 3/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trientine SCHEMBL14343015 | 1.00 | LMNA (0.58) | LMNACA12CA6CA7CA9 | |
| Trientine SCHEMBL506363 | 1.00 | LMNA (0.58) | LMNACA12CA6CA7CA9 | |
| Succinic Acid SCHEMBL2447637 | 1.00 | LMNA (0.58) | LMNACA12CA6CA7CA9 | |
| Succinic Acid SCHEMBL2449729 | 0.97 | LMNA (0.57) | LMNACA12CA6CA7CA9 | |
| Succinic Acid SCHEMBL3778716 | 0.97 | LMNA (0.57) | LMNACA12CA6CA7CA9 | |
| SCHEMBL18814471 | 0.92 | LMNA (0.55) | LMNACA12CA6CA7CA9 | |
| Adipic Acid SCHEMBL11873219 | 0.92 | NFKB1 (0.64) | LMNACA12CA6CA7CA9 | |
| Trientine SCHEMBL11876109 | 0.92 | NFKB1 (0.64) | LMNACA12CA6CA7CA9 | |
| SCHEMBL16638651 | 0.92 | LMNA (0.55) | LMNACA12CA6CA7CA9 | |
| Adipic Acid SCHEMBL4681431 | 0.92 | NFKB1 (0.64) | LMNACA12CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017213524-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS | COOPER GARTH (NZ) | 2017-12-14 | — | — | WO | claimed |
| US-20150196500-A1 | Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits | PHILERA NEW ZEALAND LIMITED (NZ) | 2015-07-16 | — | — | US | claimed |
| US-20130108709-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2013-05-02 | — | — | US | claimed |
| US-20100160428-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2010-06-24 | — | — | US | claimed |
| US-20090093542-A1 | Copper antagonist compositions | COOPER GARTH J S | 2009-04-09 | — | — | US | claimed |
| US-20090093506-A1 | Copper antagonist compositions | COOPER GARTH J S | 2009-04-09 | — | — | US | claimed |
| EP-1948160-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | Protemix Corporation Limited (NZ) | 2008-07-30 | — | — | EP | claimed |
| WO-2007055598-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | PROTEMIX CORPORATION LIMITED (NZ) | 2007-05-18 | — | — | WO | claimed |
| WO-2006104398-A1 | COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
| WO-2006104397-A1 | COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
| WO-2006104399-A1 | COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
| WO-2006104401-A1 | COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
| WO-2006104400-A1 | COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
| WO-2006104402-A1 | COPPER ANTAGONIST COMPOSITIONS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-10-05 | — | — | WO | claimed |
| WO-2006068516-A1 | IMPLANTABLE MEDICAL DEVICES COATED WITH OR CONTAINING COPPER CHELATING COMPOUNDS | PROTEMIX CORPORATION LIMITED (NZ) | 2006-06-29 | — | — | WO | claimed |
| US-5691120-A | PHOTOGRAPHY | EASTMAN KODAK COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-5652085-A | BLEACHING/FIXING PHOTOGRAPHIC FILMS | EASTMAN KODAK COMPANY (US) | 1997-07-29 | — | — | US | claimed |
| EP-4565559-A1 | METHOD FOR TRIETHYLENETETRAMINE PURIFICATION | Philera New Zealand Ltd. (NZ) | 2025-06-11 | — | — | EP | disclosed |
| EP-0762203-A1 | Succinic acid derivative degradable chelants, uses and compositions thereof | EASTMAN KODAK COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1997008288-A1 | SUCCINIC ACID DERIVATIVE DEGRADABLE CHELANTS, USES AND COMPOSITIONS THEREOF | THE DOW CHEMICAL COMPANY (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160428-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | CS, GOT2, COX5B | SLC6A2 867/4885LMNA 1698/4885CA12 3267/4885 |
| US-20130108709-A1 | TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS | TFAM, NDUFAB1, HSPA9 | SLC6A2 3012/4885LMNA 683/4885CA12 4517/4885 |
| US-20090093506-A1 | Copper antagonist compositions | HMGCR, SLC10A1, PCSK9 | SLC6A2 251/4885LMNA 3654/4885CA12 2335/4885 |
| US-20150196500-A1 | Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits | TFAM, NDUFAB1, HSPA9 | SLC6A2 3012/4885LMNA 683/4885CA12 4517/4885 |
| US-20090093542-A1 | Copper antagonist compositions | ACE, CTRB2, AGTR2 | SLC6A2 21/4885LMNA 3370/4885CA12 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.